https://cyndrx.com/wp-content/uploads/2022/05/May-31-2022-Press-Release.jpg7201500cyndrx2026https://cyndrx.com/wp-content/uploads/2026/04/ol-cmyk-CyndRx-Logo-2020-patients-first-no-period-WEB-scaled.pngcyndrx20262022-05-31 15:20:002026-05-14 19:36:35CyndRx has begun enrollment in the SEAL TO HEAL U.S. IDE clinical trial to assess the safety and effectiveness of the AbsorbaSeal™ 5.6.7F Vascular Closure Device.
https://cyndrx.com/wp-content/uploads/2022/02/February-9-2022-Press-Release-copy.jpg7201500cyndrx2026https://cyndrx.com/wp-content/uploads/2026/04/ol-cmyk-CyndRx-Logo-2020-patients-first-no-period-WEB-scaled.pngcyndrx20262022-02-09 21:19:002026-05-14 19:37:08CyndRx, LLC Receives Full FDA Approval of Investigational Device Exemption (IDE) to Initiate a U.S. Pivotal Trial for the AbsorbaSeal™ 5.6.7F Vascular Closure Device
https://cyndrx.com/wp-content/uploads/2021/03/March-30-2021-Press-Release-copy.jpg7201500cyndrx2026https://cyndrx.com/wp-content/uploads/2026/04/ol-cmyk-CyndRx-Logo-2020-patients-first-no-period-WEB-scaled.pngcyndrx20262021-03-30 21:46:002026-05-14 19:38:02CyndRx, LLC Finalizes CE Mark Trial with Strong Clinical Outcomes using AbsorbaSeal™ Vascular Closure Device
https://cyndrx.com/wp-content/uploads/2020/12/December-11-2020-Press-Release-copy.jpg7201500cyndrx2026https://cyndrx.com/wp-content/uploads/2026/04/ol-cmyk-CyndRx-Logo-2020-patients-first-no-period-WEB-scaled.pngcyndrx20262020-12-11 21:55:002026-05-14 19:38:34CyndRx, LLC Announces Completion of Enrollment in the AbsorbaSeal™ Vascular Closure Device CE Mark Trial
https://cyndrx.com/wp-content/uploads/2020/10/October-7-2020-Press-Release.jpg7201500cyndrx2026https://cyndrx.com/wp-content/uploads/2026/04/ol-cmyk-CyndRx-Logo-2020-patients-first-no-period-WEB-scaled.pngcyndrx20262020-10-07 21:52:002026-05-14 19:38:48CyndRx, LLC Enrolls First Patients in the AbsorbaSeal™ Vascular Closure Device CE Mark Trial
